E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC-Outcomes based on chemotherapy subsets. Wakelee, H. A., Dahlberg, S., Keller, S. M., Tester, W. J., Gandara, D. R., Graziano, S. L., Adjei, A. A., Leighl, N. B., Butts, C., Aisner, S. C., Rothman, J. M., Patel, J. D., Sborov, M. D., McDermott, R. S., Perez-Soler, R., Traynor, A. M., Evans, T. L., Horn, L., Ramalingam, S. S., Schiller, J. H. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.8507

View details for Web of Science ID 000404711505239